{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:50:35Z","timestamp":1790239835261,"version":"4.1.0"},"reference-count":266,"publisher":"Harborside Press, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p>Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, anaplastic lymphoma kinase\u2013positive, anaplastic large cell lymphoma, anaplastic lymphoma kinase\u2013negative, and enteropathy-associated T-cell lymphoma. This discussion section focuses on the diagnosis and treatment of PTCLs as outlined in the NCCN Guidelines for T-Cell Lymphomas.<\/jats:p>","DOI":"10.6004\/jnccn.2022.0015","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T11:27:52Z","timestamp":1646998072000},"page":"285-308","source":"Crossref","is-referenced-by-count":149,"title":["T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology"],"prefix":"10.6004","volume":"20","author":[{"given":"Steven M.","family":"Horwitz","sequence":"first","affiliation":[{"name":"1Memorial Sloan Kettering Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Ansell","sequence":"additional","affiliation":[{"name":"2Mayo Clinic Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyun Z.","family":"Ai","sequence":"additional","affiliation":[{"name":"3UCSF Helen Diller Family Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Barnes","sequence":"additional","affiliation":[{"name":"4Massachusetts General Hospital Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[{"name":"5Abramson Cancer Center at the University of Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Brammer","sequence":"additional","affiliation":[{"name":"6The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Clemens","sequence":"additional","affiliation":[{"name":"7The University of Texas MD Anderson Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[{"name":"1Memorial Sloan Kettering Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Foss","sequence":"additional","affiliation":[{"name":"8Yale Cancer Center\/Smilow Cancer Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ghione","sequence":"additional","affiliation":[{"name":"9Roswell Park Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Goodman","sequence":"additional","affiliation":[{"name":"10UC San Diego Moores Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Guitart","sequence":"additional","affiliation":[{"name":"11Robert H. Lurie Comprehensive Cancer Center of Northwestern University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Halwani","sequence":"additional","affiliation":[{"name":"12Huntsman Cancer Institute at the University of Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley M.","family":"Haverkos","sequence":"additional","affiliation":[{"name":"13University of Colorado Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"14Stanford Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"15Dana-Farber\/Brigham and Women's Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Jagadeesh","sequence":"additional","affiliation":[{"name":"16Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Jones","sequence":"additional","affiliation":[{"name":"17St. Jude Children's Research Hospital\/The University of Tennessee Health Science Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avyakta","family":"Kallam","sequence":"additional","affiliation":[{"name":"18Fred & Pamela Buffett Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn H.","family":"Kim","sequence":"additional","affiliation":[{"name":"14Stanford Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Kumar","sequence":"additional","affiliation":[{"name":"19UT Southwestern Simmons Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[{"name":"20Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise A.","family":"Olsen","sequence":"additional","affiliation":[{"name":"21Duke Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh A.","family":"Rajguru","sequence":"additional","affiliation":[{"name":"22University of Wisconsin Carbone Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Rozati","sequence":"additional","affiliation":[{"name":"23The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Said","sequence":"additional","affiliation":[{"name":"24UCLA Jonsson Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Shaver","sequence":"additional","affiliation":[{"name":"25Vanderbilt-Ingram Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Shea","sequence":"additional","affiliation":[{"name":"26O'Neal Comprehensive Cancer Center at UAB;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michi M.","family":"Shinohara","sequence":"additional","affiliation":[{"name":"27Fred Hutchinson Cancer Research Center\/Seattle Cancer Care Alliance;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubomir","family":"Sokol","sequence":"additional","affiliation":[{"name":"28Moffitt Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Torres-Cabala","sequence":"additional","affiliation":[{"name":"7The University of Texas MD Anderson Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Wilcox","sequence":"additional","affiliation":[{"name":"29University of Michigan Rogel Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Wu","sequence":"additional","affiliation":[{"name":"30UC Davis Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Zain","sequence":"additional","affiliation":[{"name":"31City of Hope National Medical Center; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Dwyer","sequence":"additional","affiliation":[{"name":"32National Comprehensive Cancer Network."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Sundar","sequence":"additional","affiliation":[{"name":"32National Comprehensive Cancer Network."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref1291","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2679.2679","article-title":"Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed\/refractory peripheral T-cell lymphomas: minimal benefit when analyzed by intent to treat [abstract]","volume":"106","author":"Horwitz","year":"2005","journal-title":"Blood"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1200\/JCO.2000.18.4.795","article-title":"Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center","volume":"18","author":"Gale","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref1281","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer"},{"key":"ref2401","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"ref1251","first-page":"203","article-title":"Cyclosporine treatment of angioimmunoblastic T-cell lymphoma relapsed after an autologous hematopoietic stem cell transplant","volume":"13","author":"Wang","year":"2015","journal-title":"Exp Clin Transplant"},{"key":"ref2641","article-title":"Gemcitabine, dexamethasone, and cisplatin (GDP) as secondary chemotherapy in relapsed\/refractory peripheral T-cell lymphoma [abstract]","volume":"122","author":"Connors","year":"2013","journal-title":"Blood"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","article-title":"Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect","volume":"26","author":"Dodero","year":"2012","journal-title":"Leukemia"},{"key":"ref2081","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","article-title":"Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group","volume":"79","author":"Rodr\u00edguez","year":"2007","journal-title":"Eur J Haematol"},{"key":"ref2271","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","article-title":"Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience","volume":"14","author":"Chen","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.23992","article-title":"Treatment response in enteropathy associated T-cell lymphoma; survival in a large multicenter cohort","volume":"90","author":"Nijeboer","year":"2015","journal-title":"Am J Hematol"},{"key":"ref1411","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"ref2621","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer"},{"key":"ref1581","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41409-019-0732-9","article-title":"Allogeneic hematopoietic stem cell transplantation for patients with relapsed\/refractory systemic anaplastic large cell lymphoma: a retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"55","author":"Domingo-Dom\u00e8nech","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"ref1471","first-page":"2697","article-title":"ALK+ lymphoma: clinico-pathological findings and outcome","volume":"93","author":"Falini","year":"1999","journal-title":"Blood"},{"key":"ref2391","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci\u00e9t\u00e9 Francaise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref2321","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci\u00e9t\u00e9 Francaise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref1391","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"ref2491","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/ajh.25043","article-title":"Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): a phase 1b open-label study","volume":"93","author":"Gambacorti-Passerini","year":"2018","journal-title":"Am J Hematol"},{"key":"ref21","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"key":"ref2121","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of up-front autologous stem cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Ann Oncol"},{"key":"ref1431","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ajcp\/aqab090","article-title":"How I diagnose angioimmunoblastic T-cell lymphoma","volume":"156","author":"Xie","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood.2019000779","article-title":"Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry","volume":"134","author":"Amador","year":"2019","journal-title":"Blood"},{"key":"ref2221","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3109\/10428194.2010.529208","article-title":"Report on the Second International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 8-9 April 2010","volume":"51","author":"Meignan","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2007.06725.x","article-title":"Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases","volume":"138","author":"Willenbrock","year":"2007","journal-title":"Br J Haematol"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"key":"ref2351","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13045-018-0696-z","article-title":"Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis","volume":"12","author":"Epperla","year":"2019","journal-title":"J Hematol Oncol"},{"key":"ref1731","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/asheducation-2006.1.317","article-title":"Pathobiology of peripheral T-cell lymphomas","volume":"2006","author":"Jaffe","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref2521","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3324\/haematol.2017.167742","article-title":"Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707","volume":"102","author":"Maeda","year":"2017","journal-title":"Haematologica"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1704367","article-title":"Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey","volume":"33","author":"Jantunen","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"ref641","first-page":"218","article-title":"High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Kyriakou","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","article-title":"Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience","volume":"14","author":"Chen","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref2091","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"ref1461","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"key":"ref1301","article-title":"Gemcitabine, dexamethasone, and cisplatin (GDP) as secondary chemotherapy in relapsed\/refractory peripheral T-cell lymphoma [abstract]","volume":"122","author":"Connors","year":"2013","journal-title":"Blood"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0609.2007.00815.x","article-title":"Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience","volume":"78","author":"Rodr\u00edguez","year":"2007","journal-title":"Eur J Haematol"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref2181","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2967\/jnumed.117.193946","article-title":"Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients","volume":"59","author":"Cottereau","year":"2018","journal-title":"J Nucl Med"},{"key":"ref2231","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3109\/10428194.2012.677535","article-title":"Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus","volume":"53","author":"Meignan","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"ref2371","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000500666","article-title":"Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE Registry","volume":"143","author":"Lansigan","year":"2020","journal-title":"Acta Haematol"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1046\/j.1365-2141.2003.04203.x","article-title":"Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype","volume":"120","author":"Song","year":"2003","journal-title":"Br J Haematol"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2141.2006.06371.x","article-title":"Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma","volume":"136","author":"Bishton","year":"2007","journal-title":"Br J Haematol"},{"key":"ref1661","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjh.15258","article-title":"Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS): a new prognostic model developed by the International T cell Project Network","volume":"181","author":"Federico","year":"2018","journal-title":"Br J Haematol"},{"key":"ref1791","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"ref1541","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1093\/annonc\/mdh427","article-title":"Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma","volume":"15","author":"W\u00f6hrer","year":"2004","journal-title":"Ann Oncol"},{"key":"ref2361","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41409-019-0732-9","article-title":"Allogeneic hematopoietic stem cell transplantation for patients with relapsed\/refractory systemic anaplastic large cell lymphoma: a retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"55","author":"Domingo-Dom\u00e8nech","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"ref1901","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-134398","article-title":"The Echelon-2 Trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma [abstract]","volume":"136","author":"Horwitz","year":"2020","journal-title":"Blood"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/asheducation-2006.1.317","article-title":"Pathobiology of peripheral T-cell lymphomas","volume":"2006","author":"Jaffe","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1111\/bjh.15860","article-title":"Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma","volume":"186","author":"Hapgood","year":"2019","journal-title":"Br J Haematol"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/blood-2018-03-838524","article-title":"Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements","volume":"132","author":"Luchtel","year":"2018","journal-title":"Blood"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref2471","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2021-148939","article-title":"Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 Primo Trial: results of an interim analysis","volume":"138","author":"Brammer","year":"2021","journal-title":"Blood"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"ref1851","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref2551","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"ref1971","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","article-title":"Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma","volume":"37","author":"Barrington","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref1181","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci"},{"key":"ref1481","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"key":"ref2581","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/10428190601137658","article-title":"Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine","volume":"48","author":"Advani","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2012.42.2345","article-title":"Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte trials","volume":"30","author":"Sibon","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref1451","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2007.06725.x","article-title":"Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases","volume":"138","author":"Willenbrock","year":"2007","journal-title":"Br J Haematol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"key":"ref1711","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1080\/10428194.2021.1894649","article-title":"Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population","volume":"62","author":"Shirouchi","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s12185-020-02987-7","article-title":"Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma","volume":"112","author":"Suzuki","year":"2020","journal-title":"Int J Hematol"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/bloodadvances.2018024075","article-title":"Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma","volume":"3","author":"Mehta-Shah","year":"2019","journal-title":"Blood Adv"},{"key":"ref1691","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s12185-020-02987-7","article-title":"Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma","volume":"112","author":"Suzuki","year":"2020","journal-title":"Int J Hematol"},{"key":"ref2461","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1182\/blood-2019-121401","article-title":"Dose optimization of duvelisib in patients with relapsed or refractory peripheral T-cell lymphoma from the phase 2 primo Trial: selection of regimen for the dose-expansion phase [abstract]","volume":"134","author":"Horwitz","year":"2019","journal-title":"Blood"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1309\/6UTX-GVC0-12ND-JJEU","article-title":"Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified","volume":"117","author":"Zettl","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"ref1171","doi-asserted-by":"crossref","first-page":"E319","DOI":"10.1002\/ajh.25967","article-title":"Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed\/refractory to chemotherapy","volume":"95","author":"Bossi","year":"2020","journal-title":"Am J Hematol"},{"key":"ref2241","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","article-title":"High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience","volume":"14","author":"Rodr\u00edguez","year":"2003","journal-title":"Ann Oncol"},{"key":"ref2571","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref361","article-title":"Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-cell Lymphoma: a Retrospective Study [published online August 5, 2021]","author":"Kim","journal-title":"Cancer Res Treat"},{"key":"ref2211","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","article-title":"Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma","volume":"37","author":"Barrington","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref1881","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-136023","article-title":"Multi-center phase II study of oral azacitidine (CC-486) plus CHOP as initial treatment of peripheral T-cell lymphoma (PTCL) [abstract]","volume":"136","author":"Ruan","year":"2020","journal-title":"Blood"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of up-front autologous stem cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Ann Oncol"},{"key":"ref1161","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children\u2019s Oncology Group study","volume":"35","author":"Moss\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref1921","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2009-07-231324","article-title":"Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation","volume":"115","author":"Sieniawski","year":"2010","journal-title":"Blood"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1080\/10428194.2021.1894649","article-title":"Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population","volume":"62","author":"Shirouchi","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"ref2671","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ajh.25463","article-title":"Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry","volume":"94","author":"Stuver","year":"2019","journal-title":"Am J Hematol"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","article-title":"Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group","volume":"79","author":"Rodr\u00edguez","year":"2007","journal-title":"Eur J Haematol"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","article-title":"Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma","volume":"134","author":"Kewalramani","year":"2006","journal-title":"Br J Haematol"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2009-07-231324","article-title":"Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation","volume":"115","author":"Sieniawski","year":"2010","journal-title":"Blood"},{"key":"ref2341","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","article-title":"Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect","volume":"26","author":"Dodero","year":"2012","journal-title":"Leukemia"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"ref1361","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/bjh.15859","article-title":"Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas","volume":"186","author":"Ellin","year":"2019","journal-title":"Br J Haematol"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-136023","article-title":"Multi-center phase II study of oral azacitidine (CC-486) plus CHOP as initial treatment of peripheral T-cell lymphoma (PTCL) [abstract]","volume":"136","author":"Ruan","year":"2020","journal-title":"Blood"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","article-title":"High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience","volume":"14","author":"Rodr\u00edguez","year":"2003","journal-title":"Ann Oncol"},{"key":"ref2501","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children\u2019s Oncology Group study","volume":"35","author":"Moss\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2967\/jnumed.117.193946","article-title":"Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients","volume":"59","author":"Cottereau","year":"2018","journal-title":"J Nucl Med"},{"key":"ref2061","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","article-title":"The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study","volume":"40","author":"Feyler","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"ref31","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/JCO.2017.73.8195","article-title":"International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma","volume":"35","author":"Maurer","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref2051","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1704367","article-title":"Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey","volume":"33","author":"Jantunen","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"ref1861","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood Adv"},{"key":"ref1351","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1080\/10428194.2017.1393671","article-title":"Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital","volume":"59","author":"Gleeson","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"ref661","article-title":"Ten years median follow-up of the NORDIC NLG-T-01 trial on CHOEP and upfront autologous transplantation in peripheral T-cell lymphomas [abstract]","volume":"33","author":"d'Amore","year":"2015","journal-title":"Hematol Oncol"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3109\/10428194.2010.529208","article-title":"Report on the Second International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 8-9 April 2010","volume":"51","author":"Meignan","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"ref2381","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref1191","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.clml.2019.03.001","article-title":"Treatment of refractory ALK rearranged anaplastic large cell lymphoma with alectinib","volume":"19","author":"Reed","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1200\/JCO.2019.37.15_suppl.7543","article-title":"Response to brentuximab vedotin by CD30 expression: results from five trials in PTCL, CTCL, and B-cell lymphomas [abstract]","volume":"37","author":"Jagadeesh","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.bmt.1702867","article-title":"High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas","volume":"27","author":"Blystad","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"ref1221","first-page":"702","article-title":"Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma","volume":"90","author":"Zinzani","year":"2005","journal-title":"Haematologica"},{"key":"ref2421","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"key":"ref1501","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2016-12-755496","article-title":"DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study","volume":"130","author":"Pedersen","year":"2017","journal-title":"Blood"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00277-014-2227-5","article-title":"Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma","volume":"94","author":"Tomita","year":"2015","journal-title":"Ann Hematol"},{"key":"ref2201","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/hon.2697","article-title":"Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial","volume":"38","author":"Schmitz","year":"2020","journal-title":"Hematol Oncol"},{"key":"ref1991","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","article-title":"The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study","volume":"40","author":"Feyler","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"ref1891","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref2031","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41409-018-0294-2","article-title":"High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI\/Cancer Research UK Phase II Study","volume":"54","author":"Phillips","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"ref2111","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ajh.24372","article-title":"Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas","volume":"91","author":"Yam","year":"2016","journal-title":"Am J Hematol"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.3324\/haematol.2015.131151","article-title":"Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma","volume":"101","author":"Dunleavy","year":"2016","journal-title":"Haematologica"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood.2020010387","article-title":"Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"ref1551","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000205183","article-title":"Management of enteropathy-associated T-cell lymphoma: an algorithmic approach","volume":"2","author":"Babel","year":"2009","journal-title":"Case Rep Oncol"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood Adv"},{"key":"ref1741","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00000478-200604000-00009","article-title":"Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells","volume":"30","author":"Dupuis","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"key":"ref1531","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1200\/JCO.2000.18.4.795","article-title":"Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center","volume":"18","author":"Gale","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref2261","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","article-title":"Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma","volume":"134","author":"Kewalramani","year":"2006","journal-title":"Br J Haematol"},{"key":"ref1611","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1080\/10428194.2017.1393671","article-title":"Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital","volume":"59","author":"Gleeson","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"ref1601","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann Oncol"},{"key":"ref2631","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2679.2679","article-title":"Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed\/refractory peripheral T-cell lymphomas: minimal benefit when analyzed by intent to treat [abstract]","volume":"106","author":"Horwitz","year":"2005","journal-title":"Blood"},{"key":"ref1771","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.30416","article-title":"A prospective cohort study of patients with peripheral T-cell lymphoma in the United States","volume":"123","author":"Carson","year":"2017","journal-title":"Cancer"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/modpathol.3800625","article-title":"Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified","volume":"19","author":"Grogg","year":"2006","journal-title":"Mod Pathol"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"ref2591","first-page":"203","article-title":"Cyclosporine treatment of angioimmunoblastic T-cell lymphoma relapsed after an autologous hematopoietic stem cell transplant","volume":"13","author":"Wang","year":"2015","journal-title":"Exp Clin Transplant"},{"key":"ref1521","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1111\/bjh.15860","article-title":"Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma","volume":"186","author":"Hapgood","year":"2019","journal-title":"Br J Haematol"},{"key":"ref1511","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/blood-2018-03-838524","article-title":"Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements","volume":"132","author":"Luchtel","year":"2018","journal-title":"Blood"},{"key":"ref1401","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","article-title":"GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ajcp\/aqab090","article-title":"How I diagnose angioimmunoblastic T-cell lymphoma","volume":"156","author":"Xie","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ajh.24372","article-title":"Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas","volume":"91","author":"Yam","year":"2016","journal-title":"Am J Hematol"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-134398","article-title":"The Echelon-2 Trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma [abstract]","volume":"136","author":"Horwitz","year":"2020","journal-title":"Blood"},{"key":"ref761","first-page":"2646","article-title":"A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL","volume":"137","author":"Schmitz","year":"2021","journal-title":"Blood"},{"key":"ref2141","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1634\/theoncologist.2013-0463","article-title":"Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma","volume":"19","author":"Pellegrini","year":"2014","journal-title":"Oncologist"},{"key":"ref1571","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood.V93.11.3913","article-title":"Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma","volume":"93","author":"Gascoyne","year":"1999","journal-title":"Blood"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2016-12-755496","article-title":"DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study","volume":"130","author":"Pedersen","year":"2017","journal-title":"Blood"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjh.15258","article-title":"Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS): a new prognostic model developed by the International T cell Project Network","volume":"181","author":"Federico","year":"2018","journal-title":"Br J Haematol"},{"key":"ref1641","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1008418727472","article-title":"Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification","volume":"9","author":"L\u00f3pez-Guillermo","year":"1998","journal-title":"Ann Oncol"},{"key":"ref2451","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref1591","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2012.42.2345","article-title":"Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte trials","volume":"30","author":"Sibon","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1093\/annonc\/mdh427","article-title":"Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma","volume":"15","author":"W\u00f6hrer","year":"2004","journal-title":"Ann Oncol"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood.V93.11.3913","article-title":"Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma","volume":"93","author":"Gascoyne","year":"1999","journal-title":"Blood"},{"key":"ref2281","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref1831","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","article-title":"Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience","volume":"103","author":"Escal\u00f3n","year":"2005","journal-title":"Cancer"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","article-title":"Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial","volume":"35","author":"Wulf","year":"2021","journal-title":"Leukemia"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","article-title":"Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience","volume":"103","author":"Escal\u00f3n","year":"2005","journal-title":"Cancer"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000500666","article-title":"Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE Registry","volume":"143","author":"Lansigan","year":"2020","journal-title":"Acta Haematol"},{"key":"ref2531","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.clml.2019.03.001","article-title":"Treatment of refractory ALK rearranged anaplastic large cell lymphoma with alectinib","volume":"19","author":"Reed","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref1681","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/JCO.2017.73.8195","article-title":"International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma","volume":"35","author":"Maurer","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref2101","first-page":"2646","article-title":"A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL","volume":"137","author":"Schmitz","year":"2021","journal-title":"Blood"},{"key":"ref2161","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/annonc\/mdv010","article-title":"Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Horwitz","year":"2015","journal-title":"Ann Oncol"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"ref2561","first-page":"702","article-title":"Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma","volume":"90","author":"Zinzani","year":"2005","journal-title":"Haematologica"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/10428190601137658","article-title":"Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine","volume":"48","author":"Advani","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"ref1701","article-title":"Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-cell Lymphoma: a Retrospective Study [published online August 5, 2021]","author":"Kim","journal-title":"Cancer Res Treat"},{"key":"ref1811","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.3324\/haematol.2015.131151","article-title":"Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma","volume":"101","author":"Dunleavy","year":"2016","journal-title":"Haematologica"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.bbmt.2015.01.013","article-title":"Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease","volume":"21","author":"Beitinjaneh","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref1931","first-page":"1272","article-title":"Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation","volume":"88","author":"Schetelig","year":"2003","journal-title":"Haematologica"},{"key":"ref1871","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"ref2071","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/annonc\/mdl466","article-title":"The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience","volume":"18","author":"Rodr\u00edguez","year":"2007","journal-title":"Ann Oncol"},{"key":"ref2601","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13045-018-0696-z","article-title":"Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis","volume":"12","author":"Epperla","year":"2019","journal-title":"J Hematol Oncol"},{"key":"ref1781","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"ref2311","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref1721","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"key":"ref1441","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1309\/6UTX-GVC0-12ND-JJEU","article-title":"Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified","volume":"117","author":"Zettl","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/hon.2697","article-title":"Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial","volume":"38","author":"Schmitz","year":"2020","journal-title":"Hematol Oncol"},{"key":"ref591","first-page":"1272","article-title":"Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation","volume":"88","author":"Schetelig","year":"2003","journal-title":"Haematologica"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref2001","article-title":"Ten years median follow-up of the NORDIC NLG-T-01 trial on CHOEP and upfront autologous transplantation in peripheral T-cell lymphomas [abstract]","volume":"33","author":"d'Amore","year":"2015","journal-title":"Hematol Oncol"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin","volume":"102","author":"Dobay","year":"2017","journal-title":"Haematologica"},{"key":"ref2481","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"ref1321","doi-asserted-by":"crossref","first-page":"606752","DOI":"10.1155\/2015\/606752","article-title":"Gemcitabine, navelbine, and doxorubicin as treatment for patients with refractory or relapsed T-cell lymphoma","volume":"2015","author":"Qian","year":"2015","journal-title":"BioMed Res Int"},{"key":"ref1841","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","article-title":"Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial","volume":"35","author":"Wulf","year":"2021","journal-title":"Leukemia"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/annonc\/mdv010","article-title":"Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Horwitz","year":"2015","journal-title":"Ann Oncol"},{"key":"ref1981","first-page":"218","article-title":"High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Kyriakou","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref1961","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2141.2006.06371.x","article-title":"Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma","volume":"136","author":"Bishton","year":"2007","journal-title":"Br J Haematol"},{"key":"ref2171","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00277-014-2227-5","article-title":"Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma","volume":"94","author":"Tomita","year":"2015","journal-title":"Ann Hematol"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"106164","DOI":"10.1016\/j.leukres.2019.05.014","article-title":"Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib","volume":"83","author":"Tomlinson","year":"2019","journal-title":"Leuk Res"},{"key":"ref2021","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.23992","article-title":"Treatment response in enteropathy associated T-cell lymphoma; survival in a large multicenter cohort","volume":"90","author":"Nijeboer","year":"2015","journal-title":"Am J Hematol"},{"key":"ref1951","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0609.2007.00815.x","article-title":"Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience","volume":"78","author":"Rodr\u00edguez","year":"2007","journal-title":"Eur J Haematol"},{"key":"ref2331","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation","volume":"27","author":"Kyriakou","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref2541","doi-asserted-by":"crossref","first-page":"106164","DOI":"10.1016\/j.leukres.2019.05.014","article-title":"Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib","volume":"83","author":"Tomlinson","year":"2019","journal-title":"Leuk Res"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41409-019-0734-7","article-title":"Autologous hematopoietic stem cell transplantation for relapsed\/refractory systemic anaplastic large cell lymphoma: a retrospective analysis of the lymphoma working party (LWP) of the EBMT","volume":"55","author":"Domingo-Dom\u00e8nech","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"ref2151","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.24128","article-title":"Utility of interim and end-of-treatment PET\/CT in peripheral T-cell lymphomas: a review of 124 patients","volume":"90","author":"El-Galaly","year":"2015","journal-title":"Am J Hematol"},{"key":"ref1371","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"key":"ref2651","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00277-015-2468-y","article-title":"Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial","volume":"94","author":"Park","year":"2015","journal-title":"Ann Hematol"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.30416","article-title":"A prospective cohort study of patients with peripheral T-cell lymphoma in the United States","volume":"123","author":"Carson","year":"2017","journal-title":"Cancer"},{"key":"ref1651","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"key":"ref1801","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14740","article-title":"The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study","volume":"178","author":"Cederleuf","year":"2017","journal-title":"Br J Haematol"},{"key":"ref1941","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"key":"ref2251","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1046\/j.1365-2141.2003.04203.x","article-title":"Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype","volume":"120","author":"Song","year":"2003","journal-title":"Br J Haematol"},{"key":"ref2441","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref1761","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin","volume":"102","author":"Dobay","year":"2017","journal-title":"Haematologica"},{"key":"ref1491","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00000478-200604000-00009","article-title":"Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells","volume":"30","author":"Dupuis","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/annonc\/mdl466","article-title":"The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience","volume":"18","author":"Rodr\u00edguez","year":"2007","journal-title":"Ann Oncol"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation","volume":"27","author":"Kyriakou","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref1821","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3324\/haematol.2017.167742","article-title":"Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707","volume":"102","author":"Maeda","year":"2017","journal-title":"Haematologica"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/bloodadvances.2020001581","article-title":"ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project","volume":"5","author":"Shustov","year":"2021","journal-title":"Blood Adv"},{"key":"ref2301","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41409-019-0734-7","article-title":"Autologous hematopoietic stem cell transplantation for relapsed\/refractory systemic anaplastic large cell lymphoma: a retrospective analysis of the lymphoma working party (LWP) of the EBMT","volume":"55","author":"Domingo-Dom\u00e8nech","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00277-016-2891-8","article-title":"Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP\/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment","volume":"96","author":"Kitahara","year":"2017","journal-title":"Ann Hematol"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3109\/10428194.2012.677535","article-title":"Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus","volume":"53","author":"Meignan","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"ref131","first-page":"2697","article-title":"ALK+ lymphoma: clinico-pathological findings and outcome","volume":"93","author":"Falini","year":"1999","journal-title":"Blood"},{"key":"ref2291","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.bbmt.2015.01.013","article-title":"Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease","volume":"21","author":"Beitinjaneh","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref1311","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00277-015-2468-y","article-title":"Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial","volume":"94","author":"Park","year":"2015","journal-title":"Ann Hematol"},{"key":"ref1621","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/bloodadvances.2020001581","article-title":"ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project","volume":"5","author":"Shustov","year":"2021","journal-title":"Blood Adv"},{"key":"ref2511","doi-asserted-by":"crossref","first-page":"E319","DOI":"10.1002\/ajh.25967","article-title":"Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed\/refractory to chemotherapy","volume":"95","author":"Bossi","year":"2020","journal-title":"Am J Hematol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2011-02-335216","article-title":"Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project","volume":"118","author":"Delabie","year":"2011","journal-title":"Blood"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2021-148939","article-title":"Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 Primo Trial: results of an interim analysis","volume":"138","author":"Brammer","year":"2021","journal-title":"Blood"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.24128","article-title":"Utility of interim and end-of-treatment PET\/CT in peripheral T-cell lymphomas: a review of 124 patients","volume":"90","author":"El-Galaly","year":"2015","journal-title":"Am J Hematol"},{"key":"ref2611","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"key":"ref2411","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14740","article-title":"The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study","volume":"178","author":"Cederleuf","year":"2017","journal-title":"Br J Haematol"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1634\/theoncologist.2013-0463","article-title":"Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma","volume":"19","author":"Pellegrini","year":"2014","journal-title":"Oncologist"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/ajh.25043","article-title":"Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): a phase 1b open-label study","volume":"93","author":"Gambacorti-Passerini","year":"2018","journal-title":"Am J Hematol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref1331","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ajh.25463","article-title":"Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry","volume":"94","author":"Stuver","year":"2019","journal-title":"Am J Hematol"},{"key":"ref1561","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2011-02-335216","article-title":"Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project","volume":"118","author":"Delabie","year":"2011","journal-title":"Blood"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann Oncol"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1008418727472","article-title":"Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification","volume":"9","author":"L\u00f3pez-Guillermo","year":"1998","journal-title":"Ann Oncol"},{"key":"ref1381","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"key":"ref2131","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00277-016-2891-8","article-title":"Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP\/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment","volume":"96","author":"Kitahara","year":"2017","journal-title":"Ann Hematol"},{"key":"ref1631","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood.2020010387","article-title":"Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000205183","article-title":"Management of enteropathy-associated T-cell lymphoma: an algorithmic approach","volume":"2","author":"Babel","year":"2009","journal-title":"Case Rep Oncol"},{"key":"ref2011","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1182\/blood-2019-121401","article-title":"Dose optimization of duvelisib in patients with relapsed or refractory peripheral T-cell lymphoma from the phase 2 primo Trial: selection of regimen for the dose-expansion phase [abstract]","volume":"134","author":"Horwitz","year":"2019","journal-title":"Blood"},{"key":"ref2041","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.bmt.1702867","article-title":"High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas","volume":"27","author":"Blystad","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"ref2661","doi-asserted-by":"crossref","first-page":"606752","DOI":"10.1155\/2015\/606752","article-title":"Gemcitabine, navelbine, and doxorubicin as treatment for patients with refractory or relapsed T-cell lymphoma","volume":"2015","author":"Qian","year":"2015","journal-title":"BioMed Res Int"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref1271","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"key":"ref1671","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/bjh.15859","article-title":"Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas","volume":"186","author":"Ellin","year":"2019","journal-title":"Br J Haematol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","article-title":"GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41409-018-0294-2","article-title":"High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI\/Cancer Research UK Phase II Study","volume":"54","author":"Phillips","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"ref1421","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood.2019000779","article-title":"Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry","volume":"134","author":"Amador","year":"2019","journal-title":"Blood"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref1751","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/modpathol.3800625","article-title":"Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified","volume":"19","author":"Grogg","year":"2006","journal-title":"Mod Pathol"},{"key":"ref2191","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/bloodadvances.2018024075","article-title":"Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma","volume":"3","author":"Mehta-Shah","year":"2019","journal-title":"Blood Adv"},{"key":"ref1911","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1200\/JCO.2019.37.15_suppl.7543","article-title":"Response to brentuximab vedotin by CD30 expression: results from five trials in PTCL, CTCL, and B-cell lymphomas [abstract]","volume":"37","author":"Jagadeesh","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref2431","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/3\/article-p285.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/20\/3\/article-p285.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T16:38:45Z","timestamp":1674923925000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/3\/article-p285.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":266,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2022.0015","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}